Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia

Leukemia Research

Volumn 34, Issue 4, 2010, Pages 487-491

  Allen, Steven L ^a   Kolitz, Jonathan E ^b   Lundberg, Ante S ^c   Bennett, John M ^d   Capizzi, Robert L ^c   Budman, Daniel R ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b North Shore Long Island Center for Advanced Medicine   (United States)

^c Antisoma Research Limited   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

AML; Multidrug resistance; P glycoprotein; Pgp; Phase I

Indexed keywords

AMONAFIDE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; EXFOLIATIVE DERMATITIS; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; HYPOTENSION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSAL DISEASE; NAUSEA; ODYNOPHAGIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RASH; SEPSIS; SIDE EFFECT; SKIN DISCOLORATION; SORE THROAT; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NAPHTHALIMIDES; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76749136625     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.038     Document Type: Article

References (27)

1. Kimby E., Nygren P., and Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 40 (2001) 231-252
2. Godwin J.E., Kopecky K.J., Head D.R., et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 91 (1998) 3607-3615
3. Leith C.P., Kopecky K.J., Godwin J., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89 (1997) 3323-3329
4. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 107 (2006) 3481-3485
5. Estey E., and Dohner H. Acute myeloid leukaemia. Lancet 368 (2006) 1894-1907
6. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5 (2006) 219-234
7. Otake Y., Chau M., Ajami A.M., and Fernandes D.J. Amonafide interferes with topoisomerase II binding to DNA and induces chromatin disorganization. Proc AACR 49 (2008) 152
8. Sami S.M., Dorr R.T., Alberts D.S., Solyom A.M., and Remers W.A. 2-[2′-(Dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships. J Med Chem 39 (1996) 4978-4987
9. Sami S.M., Dorr R.T., Solyom A.M., Alberts D.S., Iyengar B.S., and Remers W.A. 6- and 7-Substituted 2-[2′-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships. J Med Chem 39 (1996) 1609-1618
10. Chau M., Christensen J.L., Ajami A.M., and Capizzi R.L. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 32 (2008) 465-473
11. Burcu M., O'Loughlin K.L., Ford L.A., and Baer M.R. Amonafide l-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia 22 (2008) 2110-2115
12. O'Brien S., Benvenuto J.A., Estey E., Beran M., Felder T.B., and Keating M. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 51 (1991) 935-938
13. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
14. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
15. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62 (1993) 385-427
16. Greenberg P.L., Lee S.J., Advani R., et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 22 (2004) 1078-1086
17. Baer M.R. Clinical significance of multidrug resistance in AML: current insights. Clin Adv Hematol Oncol 3 (2005) 910-912
18. Benderra Z., Faussat A.M., Sayada L., et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11 (2005) 7764-7772
19. Benderra Z., Faussat A.M., Sayada L., et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10 (2004) 7896-7902
20. Wuchter C., Leonid K., Ruppert V., et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 85 (2000) 711-721
21. Damiani D., Tiribelli M., Raspadori D., et al. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematol Oncol 25 (2007) 38-43
22. Baer M.R., George S.L., Dodge R.K., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100 (2002) 1224-1232
23. List A.F., Kopecky K.J., Willman C.L., et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 (2001) 3212-3220
24. Kolitz J.E., George S.L., Dodge R.K., et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22 (2004) 4290-4301
25. van der Holt B., Lowenberg B., Burnett A.K., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106 (2005) 2646-2654
26. Cripe L.D., Li X., Litzow M., et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for Pts > 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. Blood 108 (2006) 129a
27. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96 (2000) 4075-4083